Annual Information Update

Oxford Biomedica PLC
03 April 2008


For Immediate Release                                               3 April 2008


                              Oxford BioMedica plc
                     ('Oxford BioMedica' or the 'Company')


        Annual Information Update for the Twelve Months to 2 April 2008


Oxford BioMedica is providing an annual information update pursuant to
Prospectus Rule 5.2 made by the Financial Services Authority.


1. Announcements made via a Regulatory Information Service

Date                     Announcement

3 April 2007             Directors' interests in shares and share options
7 April 2007             Holding(s) in Company
16 April 2007            Annual information update
27 April 2007            Directors' interests in shares and share options
30 April 2007            Holding(s) in Company
30 April 2007            Total voting rights update
1 May 2007               RetinoStat and StarGen preclinical data presented
3 May 2007               AGM statement
7 May 2007               Avian Transgenic project update
17 May 2007              Hi-8 MEL clinical data presentation
17 May 2007              Blocklisting interim review
22 May 2007              Holding(s) in Company
24 May 2007              Corporate presentation at FBR Growth conference
29 May 2007              Notice of TroVax clinical data presentation
31 May 2007              Total voting rights update
3 June 2007              TroVax clinical data presentation
18 June 2007             Corporate presentation at Piper Jaffrey healthcare 
                         conference
22 June 2007             TechMark Mediscience breakthrough of the year award
22 June 2007             Viragen transgenic collaboration terminated
28 June 2007             Holding(s) in Company
29 June 2007             Total voting rights update
2 July 2007              LentiVector licence with major biotechnology company
6 July 2007              Licence for anti-cancer genes and share subscription
25 July 2007             TroVax Phase III DSMB positive review
31 July 2007             Total voting rights update
2 August 2007            Publication of TroVax phase II clinical data
2 August 2007            Holding(s) in Company
3 August 2007            Holding(s) in Company
29 August 2007           Holding(s) in Company
30 August 2007           Holding(s) in Company
31 August 2007           Total voting rights update
11 September 2007        TroVax collaboration milestone
11 September 2007        Interim results
28 September 2007        Holding(s) in Company
22 October 2007          Directors' interests in shares and share options
25 October 1007          Business update and comment on share price movement
25 October 2007          Directors' interests in shares and share options
26 October 2007          Litigation against Open Biosystems - favourable ruling
9 November 2007          Change of broker - appointment of JP Morgan Cazenove
16 November 2007         Blocklisting interim review
29 November 2007         TechMark achievement of the year award
5 December 2007          Scrip licensing deal of the year award
6 December 2007          Holding(s) in Company
10 December 2007         TroVax Phase III DSMB positive review
13 December 2007         ProSavin initiation of Phase I/II clinical trial
18 December 2007         Holding(s) in Company
7 January 2008           Licence for RNAi technology and share subscription
18 January 2008          Holding(s) in Company
22 January 2008          Milestone in collaboration with Molmed S.p.A
22 January 2008          Holding(s) in Company
29 January 2008          Holding(s) in Company
31 January 2008          Total voting rights update
1 February 2008          Holding(s) in Company
7 February 2008          Notice of results
13 February 2008         Holding(s) in Company
14 February 2008         Holding(s) in Company
19 February 2008         Holding(s) in Company
20 February 2008         TroVax Phase III DSMB positive review and collaboration 
                         milestone
29 February 2008         Total voting rights update
10 March 2008            TroVax Phase III clinical trial completion of
                         recruitment
10 March 2008            Appointment of non-executive director
10 March 2008            Preliminary results for 2007
13 March 2008            Directors' interests in shares and share options
17 March 2008            Corporate presentation at Cowen & Co. healthcare 
                         conference
18 March 2008            Holding(s) in Company
25 March 2008            TroVax clinical data presentation
31 March 2008            Total voting rights update
1 April 2008             Holding(s) in Company
2 April 2008             Annual information update


Details of all regulatory announcements for Oxford BioMedica can be found on the
London Stock Exchange website at www.londonstockexchange.com and on the Oxford
BioMedica website at http://www.oxfordbiomedica.co.uk


2. Documents filed with Companies House

           Date                Document Type               Description

   26 September 88(2) Return of Allotment of  Allotment 122,815 1p Ord.
           2007 shares

   26 September 88(2) Return of Allotment of  Allotment 414,162 1p Ord.
           2007 shares

   26 September 88(2) Return of Allotment of  Allotment 394,617 1p Ord.
           2007 shares

   26 September 88(2) Return of Allotment of  Allotment 144,631 1p Ord.
           2007 shares

   26 September 363s Annual Return
           2007

  14 March 2008 288a Appointment of director  Dr Alex Lewis

   2 April 2008 88(2) Return of Allotment of  Allotment 2,418,473 1p
                shares                        Ord.


Copies of documents filed at Companies House can be obtained from Companies
House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at
www.direct.companieshouse.gov.uk


3. Documents published or sent to shareholders or filed with the UKLA Viewing
   Facility

Date                 Description

21 September 2007    Interim Report for 6 months to 30 June 2007


Copies of all the above documents may be obtained from the Company Secretary at
the Company's Registered Office:


This annual information update is filed pursuant to Prospectus Rule 5.2 made by
the Financial Services Authority and not for any other purpose and by filing
this annual information update neither the Company, nor any other person, takes
any responsibility for, or makes any representation, express or implied, as to
the accuracy or completeness of, the information contained or referred to below
herein. The information referred to below is not necessarily up to date as at
the date of this annual information update and the Company does not undertake
any obligation to update any such information in the future. Furthermore, such
information may have been prepared in accordance with the laws or regulations of
a particular jurisdiction and may not comply with or meet the relevant standards
of disclosure in any other jurisdiction. Neither this annual information update,
nor the information referred to below constitutes, by virtue of this
communication, an offer of any securities addressed to any person and should not
be relied on by any person.


Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford

OX4 4GA

2 April 2008


For further information, please contact:

For further information, please contact:

Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive     Tel: [phone]

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson                   Tel: [phone]

City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: [phone]

Buchanan Communications

Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout    Tel: [phone]

College Hill Life Sciences

US Enquiries:

Thomas Fechtner                              Tel: [phone]

The Trout Group LLC


                      This information is provided by RNS
            The company news service from the London Stock Exchange